Pharmaron Beijing Co Stock Net Income
| 300759 Stock | 26.95 0.23 0.86% |
Pharmaron Beijing Co fundamentals help investors to digest information that contributes to Pharmaron Beijing's financial success or failures. It also enables traders to predict the movement of Pharmaron Stock. The fundamental analysis module provides a way to measure Pharmaron Beijing's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharmaron Beijing stock.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 1.6 B | 959 M | |
| Net Income Applicable To Common Shares | 1.9 B | 2 B | |
| Net Income | 1.6 B | 975.9 M |
Pharmaron | Net Income |
Pharmaron Beijing Co Company Net Income Analysis
Pharmaron Beijing's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Pharmaron Beijing Net Income | 1.6 B |
Most of Pharmaron Beijing's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharmaron Beijing Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Pharmaron Net Interest Income
Net Interest Income |
|
Based on the recorded statements, Pharmaron Beijing Co reported net income of 1.6 B. This is 369.14% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The net income for all China stocks is 180.41% lower than that of the firm.
Pharmaron Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharmaron Beijing's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pharmaron Beijing could also be used in its relative valuation, which is a method of valuing Pharmaron Beijing by comparing valuation metrics of similar companies.Pharmaron Beijing is currently under evaluation in net income category among its peers.
Pharmaron Fundamentals
| Return On Equity | 0.14 | ||||
| Return On Asset | 0.0415 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 46.66 B | ||||
| Shares Outstanding | 1.49 B | ||||
| Shares Owned By Insiders | 42.12 % | ||||
| Shares Owned By Institutions | 21.88 % | ||||
| Price To Book | 3.57 X | ||||
| Price To Sales | 3.99 X | ||||
| Revenue | 11.54 B | ||||
| Gross Profit | 2.68 B | ||||
| EBITDA | 2.39 B | ||||
| Net Income | 1.6 B | ||||
| Total Debt | 577.07 M | ||||
| Book Value Per Share | 7.57 X | ||||
| Cash Flow From Operations | 2.75 B | ||||
| Earnings Per Share | 1.06 X | ||||
| Target Price | 27.8 | ||||
| Number Of Employees | 20.3 K | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 49.1 B | ||||
| Total Asset | 26.48 B | ||||
| Retained Earnings | 5.2 B | ||||
| Working Capital | 7.22 B | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 26.48 B | ||||
| Last Dividend Paid | 0.2 |
About Pharmaron Beijing Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharmaron Beijing Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmaron Beijing using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmaron Beijing Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Pharmaron Stock
Pharmaron Beijing financial ratios help investors to determine whether Pharmaron Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharmaron with respect to the benefits of owning Pharmaron Beijing security.